CoQ10 plus NADH: early placebo-controlled CFS study
Castro-Marrero J et al. · 2015 · Antioxidants & Redox Signaling
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Double-blind eight-week trial of CoQ10 200 mg/day plus NADH 20 mg/day or placebo.
Dose, route and schedule
Double-blind eight-week trial of CoQ10 200 mg/day plus NADH 20 mg/day or placebo.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Fatigue impact | The authors reported a lower total Fatigue Impact Scale score with the combination (p<0.05). |
The formulation combined two ingredients. The design cannot isolate either contribution.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The formulation combined two ingredients. The design cannot isolate either contribution.
Source access
Double-blind eight-week trial of CoQ10 200 mg/day plus NADH 20 mg/day or placebo.
Source reviewed 2026-11-12.
Citation and original source
Original source: Castro-Marrero J et al.. CoQ10 plus NADH: early placebo-controlled CFS study Antioxidants & Redox Signaling 2015.
Molekul research summary: https://molekul.io/research/coq10-nadh-cfs-2015. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry